权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy

利用机器学习改善化疗引起的神经病变的风险预测

基本信息

批准号：
10665536
负责人：
Alyce Sophia Adams
金额：
$ 58.96万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10665536
关键词：
Address Adjuvant Chemotherapy Adult Affect Age Awareness Biometry Breast Cancer Survivorship Caring Characteristics Chemotherapy-induced peripheral neuropathy Chronic Clinical Clinical Data Clinical Trials Colorectal Cancer Community Health Complex Computer software Decision Making Development Diagnosis Dose Dose Limiting Electronic Health Record Goals Health Services Research Impairment Individual Interview Journals Life Limb structure Machine Learning Malignant Neoplasms Mental Depression Methods Modeling Motor Nature Neuropathy Newly Diagnosed Numbness Obesity Oncology Outcome Pain Patient Care Patient Preferences Patients Peer Review Peripheral Nervous System Diseases Persons Pharmacotherapy Platinum Prevention Provider Publications Quality of life Race Reporting Risk Risk Assessment Risk Estimate Risk Factors Sample Size Statistical Models Symptoms Testing Thinking Time Toxic effect Translations Treatment Protocols Vinca Alkaloids analog associated symptom cancer care cancer epidemiology cancer invasiveness cancer therapy cancer type care systems chemotherapy chemotherapy induced neuropathy clinical decision-making community based practice comorbidity disability experience experimental study fall risk follow-up health care settings high risk improved machine learning method mathematical ability medication safety neurotoxicity older patient predictive modeling risk prediction side effect survivorship taxane tool treatment choice treatment duration

项目摘要

Project Summary/Abstract Chemotherapy-induced peripheral neuropathy (CIPN) affects more than two-thirds of adults with invasive cancer who receive select adjuvant chemotherapies (e.g., taxanes, platinum analogs). Severe CIPN symptoms can lead to chemotherapy dose reductions, treatment delays, or changes in treatment regimens; thereby affecting the potential curative effects of chemotherapy. For some patients, CIPN symptoms can persist over time, contributing to lower quality of life. Little is known about risk factors for CIPN. Chemotoxicity risk scores have been developed and evaluated for use among elderly patients receiving chemotherapy. However, these tools generally report moderate predictive accuracy (60%-70%), small sample sizes, and short-term follow up. We are aware of no publicly available, validated risk models to assess risk of severe and chronic CIPN among diverse patients at risk for this potentially disabling side effect. The goal of this proposal is to identify patients at risk for CIPN and to understand how patients and provider interpret and use CIPN risk information in clinical decision-making. Focusing on more than 8,500 insured adults (18+) diagnosed with invasive, stage I-III breast and II-IIIA colorectal cancers (2013-2021) who received adjuvant chemotherapy treatment with known risk for CIPN, we will develop and validate predictive models to quantify the risk of severe CIPN and incident chronic CIPN and assess how CIPN risk information might be used to inform clinical decision-making about cancer treatment and survivorship care planning. We hypothesize that CIPN risk is a high priority for patients in thinking about treatment choice and survivorship care planning. In addition, we hypothesize that the relative importance of CIPN risk for patient and provider decision-making will vary by patient characteristics (e.g., age, cancer stage). We anticipate that the risk of severe and chronic CIPN can be predicted with a high degree of accuracy using electronic health records and machine learning methods. The study team has significant and complementary expertise in health services research, biostatistics and predictive modeling, oncology practice, cancer epidemiology, pharmacotherapy, drug safety and the patient care experience. To our knowledge, this will be one of the first studies to develop and validate a CIPN predictive model that can be used by oncology teams to inform treatment and care planning decisions and improve patient-valued outcomes. Translation and replication of the findings will be catalyzed through publication in peer-reviewed journals and the development and distribution of free software to facilitate testing and adaptation of the resulting risk models across diverse systems of care.

项目总结/文摘